|
The US Food and Drug Administration (FDA) has granted approval for the use of Casgevy, the first CRISPR-based medicine, to treat transfusion-dependent beta thalassemia in individuals aged 12 and older. Casgevy, previously approved in December for the treatment of sickle cell disease, involves genetically modifying a patient's stem cells using the CRISPR/Cas9 gene-editing technique, then transplanting the modified cells back into the body to enhance hemoglobin production and alleviate symptoms.
|
The incidence of colorectal cancer is increasing significantly among individuals in their 30s and 40s, making it the deadliest cancer for men under 50 and the second deadliest for women under 50 (after breast cancer), according to the American Cancer Society. Even as overall cancer deaths in the U.S. continue to decline, colorectal cancer has become a leading cause of cancer death in younger adults. Experts are puzzled by the trend and suggest factors such as rising obesity rates, sedentary behavior, and unhealthy diets, or environmental factors affecting microbiomes and immune systems could be contributing to the rise.
|
The Centers for Disease Control and Prevention is recommending increased blood testing for PFAS, also known as "forever chemicals." PFAS, found in various consumer products, have been linked to potential health effects such as higher cholesterol, lower birth weight, kidney and testicular cancer, pregnancy-induced hypertension, and elevated liver enzymes.
|
The demand for cosmetic procedures, including Botox and fillers, among individuals in their 20s is reportedly rising. Younger people are seeking preventive treatments to address concerns about aging, with some undergoing procedures like Botox even before visible wrinkles appear. Social media is believed to play a significant role in shaping beauty standards and influencing younger individuals to pursue cosmetic interventions.
|
Apple is reportedly willing to remove the blood-oxygen sensor from certain watch models, including the Series 9 and Ultra 2, if the U.S. Court of Appeals doesn't grant it more leeway in a patent dispute with Masimo. Masimo obtained a favorable ruling from the U.S. International Trade Commission in October, leading Apple to temporarily stop sales of the affected watch models. Apple has appealed the ruling, and if the stay is extended, the watches with the blood-oxygen sensors can continue to be sold. However, if the stay is not extended, Apple is prepared to redesign the watches without the blood-oxygen sensor.
|
|